RAPP
Rapport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +3 | 25.15M | $1.04B | +5 | −2 |
| Q1 2026 | 69 | +1 | 25.07M | $783.61M | +5 | −4 |
| Q4 2025 | 68 | +1 | 25.43M | $771.51M | +1 | — |
| Q3 2025 | 16 | +4 | 15.68M | $465.84M | +4 | — |
| Q2 2025 | 9 | +1 | 10.01M | $113.83M | +2 | −1 |
| Q1 2025 | 5 | 0 | 1.86M | $18.69M | +1 | −1 |
| Q4 2024 | 5 | 0 | 2.06M | $36.50M | — | — |
| Q3 2024 | 4 | -2 | 1.81M | $36.50M | +1 | −3 |
| Q2 2024 | 6 | — | 2.18M | $50.21M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.05M | -23.0% | $21.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.05M | -23.0% | $21.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 487.46K | -17.7% | $9.48M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 201.75K | New | $4.13M | 0.0% | New | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 201.75K | New | $4.13M | 0.0% | New | 1 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 70.00K | 0.0% | $1.43M | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Geode Capital Management | $4.13M | 0.0% |
| Geode Capital Management | $4.13M | 0.0% |
Exited
| Millennium Management | $2.72M | was 0.0% |
| Soros Fund Management | $697,800 | was 0.0% |
| Two Sigma Investments | $302,380 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 52.47M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 404 sh · $20,160
Officer, Director · 3.66K sh · $171,837
Officer, Director · 19.50K sh · $936,846
Officer, Director · 5.79K sh · $281,721
Officer, Director · 14.17K sh · $651,492
Officer, Director · 8.37K sh · $391,280
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology